Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain Rivero-Juarez, Antonio Gutierrez Valencia, A Castaño, M Merino, D Neukam, K Ríos Villegas, Maria Jose López Ruz, Miguel Ángel Jimenez Aguilar, P Márquez, M Collado, A Gómez Vidal, A Hernández Quero, José Tellez, F Fernández Fuertes, E Rivero, A López Cortes, LF The implementation of hepatitis C (HCV) directacting antiviral drugs is prioritized in several populations in which its application provides the most immediate and impactful benefit. In this scenario, a precise knowledge of the situation of human immunodeficiency virus (HIV)/HCV chronic co-infection is required to adequately address this disease. This cross-sectional study was performed in 21 hospitals in Andalusia (Spain). The study population consisted of HIVinfected patients with an active HCV chronic infection who were not receiving HCV treatment at the time of inclusion. A total of 13,506 HIV-infected patients were included in the study. Of them, 2561 (18.9 %) presented chronic HCV infection. The majority of the patients included were on highly active antiretroviral therapy (HAART; 96.2 %), showed plasma levels with an undetectable HIV viral load (92.5 %), and had a good immunological status (median CD4+ cell count of 486 cells/mL). The HCV genotype distribution was as follows: 58.1 % were genotype 1, 1.1 % were genotype 2 2024-04-22T07:24:58Z 2024-04-22T07:24:58Z 2015 journal article Eur J Clin Microbiol Infect Dis (2015) 34:2247–2255 https://hdl.handle.net/10481/90976 10.1007/s10096-015-2476-9 eng http://creativecommons.org/licenses/by-nc-nd/3.0/ open access Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License